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have clearly documented higher bioavailibility of glucosamine
sulfate then of glucosamine hydrochloride.
Thirdly there is need for standardization of radiographic methods
and validation of new methods like MRI for easier and more
precise proof of potential retarding effect of drug on cartilage
degeneration.
Fourthly we need to know more, about exact mechanism of
action of GS. New knowledge of effect of GS on inhibition of the
cytokine intracellular signalling pathway, namely of the activation
of NF – kB is an example of this.
Fifthly there are differences in regulatory aspects of glucosamine
being registered as drug in Europe and nutritient in US that again
complicates situation.
Conclusions: Overall studies support efficacy of glucosamine.
Discrepancies may relate to product variation. NIH study will add
further to current information.
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Background: Chondroitin Sulphate (CS) is widely used through-
out the world for the treatment of osteoarthritis (OA). EULAR
recommendations include CS as a symptomatic slow acting drug
for OA (SYSADOA) in the management of both knee and hip OA
(strength of recommendation according to category 1 evidence).
However, many controversies remain to this date.
Evidence of symptomatic efficacy: Meta-analyses have shown,
that effect sizes regarding the symptomatic efficacy of CS in
published studies are high (reaching 0.8). However, effect sizes
are diminished when only high quality and large trials are con-
sidered. For both pain and functional outcomes effect sizes were
relatively consistent.
Not all studies have found significant symptomatic efficacy.
Whether this finding is based on a floor effect (very low base-
line values), patient selection, large response within the placebo
group or other factors is open to debate.
Structure modifying effect: Two large studies have examined
the structure modifying effect of CS in OA of the knee. Both stud-
ies, one one-center study and one multi-center European study
have found significant differences in the progression of disease
between treated and placebo groups over two years. Both studies
used flexed radiographic views to assess the outcome parame-
ters of joint space narrowing. In both studies automatic reading
of digitized radiographs were used. A further NIH-sponsored
large trial will be analysed within the next months with regard to
structure modification.
Open questions: Many issues regarding the treatment of CS
are still open and need appropriate assessment: Absorption
via the gastrointestinal tract; exact way of action leading to
symptomatic relief and/or structure modification; optimal dosage;
optimal origin of substance; schedule of treatment over time;
efficacy in the treatment of OA of hands and spine.
Conclusion: Overall CS appears to possess symptomatic slow
onset efficacy in OA of the hip and knee, although the effect sizes
may be smaller than suggested by the publications available. Also
current data support structure modifying effects of CS in OA of
the knee. However, much more work is needed to understand
the exact mechanisms of action all the way from the intake of the
substance to the suggested outcomes. The fact, that CS is very
well tolerated, will further stimulate ongoing work in this field.
